ESTRO 2025 - Abstract Book

S1706

Clinical - Sarcoma & skin cancer & malignant melanoma

ESTRO 2025

Conclusion: Better outcomes of SRT administered in 1 fraction versus 3 or 5 fractions and 1 target versus more targets, may be related to less advanced disease in the brain. Higher EQD2 doses had significant implications in pts prognosis. Overall, the results of this study confirm the good efficacy of SRT as a local treatment in patients with melanoma BMs.

Keywords: melanoma,brain,radiosurgery

2977

Mini-Oral Efficacy of Radiotherapy and Radiotherapy with Hyperthermia to prolong systemic therapy for patients with metastatic melanoma oligoprogerssion Aneta Maria Borkowska 1,2 , Paulina Chmiel 1 , Piotr Rutkowski 1 , Maria Telejko 2 , Hanna Koseła-Paterczyk 1 , Paulina Jagodzińska-Mucha 1 , Paweł Rogala 1 , Katarzyna Kozak 1 , Mateusz Jacek Spałek 3 1 Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 2 Department of Radiotherapy I, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland. 3 Department, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland Purpose/Objective: The use of radiotherapy (RTH) and RTH with hyperthermia (HT) as a local treatment for oligoprogression in many tumors is becoming increasingly prevalent. However, evidence supporting its efficacy in melanoma remains limited, and there is currently no evidence that radiotherapy prolongs systemic treatment in this indication. To address this